Windtree Therapeutics Inc (WINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) has a cash flow conversion efficiency ratio of 0.549x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.37 Million) by net assets ($-11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see WINT stock market capitalisation for the company's overall valuation and market capitalisation.
Windtree Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Windtree Therapeutics Inc stock price for real-time trading data and today's change.
Windtree Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Windtree Therapeutics Inc ranked by their cash flow conversion efficiency. Review Windtree Therapeutics Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GS Chain PLC
LSE:GSC
|
0.205x |
|
Eason Technology Limited
NYSE:DXF
|
-0.103x |
|
Bimi International Medical Inc
NASDAQ:BIMI
|
-0.146x |
|
Grand Vision Media Holdings PLC
LSE:GVMH
|
0.025x |
|
SRI TRANG AGR.-FOR- BA 1
F:YTAA
|
0.056x |
|
Captivision Inc
NASDAQ:CAPT
|
0.085x |
|
Mobile Global Esports Inc.
NASDAQ:MGAM
|
1.472x |
|
IMAGIN MEDICAL INC.
F:DPD3
|
N/A |
Annual Cash Flow Conversion Efficiency for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Windtree Therapeutics Inc from 1995 to 2024. Also see total assets of Windtree Therapeutics Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.00 Million | $-15.40 Million | -1.541x | +61.12% |
| 2023-12-31 | $3.39 Million | $-13.44 Million | -3.963x | -103.95% |
| 2022-12-31 | $10.01 Million | $-19.45 Million | -1.943x | -243.85% |
| 2021-12-31 | $41.88 Million | $-23.66 Million | -0.565x | -55.24% |
| 2020-12-31 | $69.55 Million | $-25.32 Million | -0.364x | -10.59% |
| 2019-12-31 | $74.94 Million | $-24.66 Million | -0.329x | -42.06% |
| 2018-12-31 | $68.11 Million | $-15.78 Million | -0.232x | -126.33% |
| 2017-12-31 | $-23.92 Million | $-21.05 Million | 0.880x | -24.48% |
| 2016-12-31 | $-28.83 Million | $-33.59 Million | 1.165x | +128.74% |
| 2015-12-31 | $8.27 Million | $-33.50 Million | -4.053x | -89.02% |
| 2014-12-31 | $19.20 Million | $-41.17 Million | -2.144x | -210.09% |
| 2013-12-31 | $58.50 Million | $-40.45 Million | -0.692x | +62.88% |
| 2012-12-31 | $17.65 Million | $-32.88 Million | -1.863x | +89.63% |
| 2011-12-31 | $1.26 Million | $-22.70 Million | -17.957x | -345.86% |
| 2010-12-31 | $6.03 Million | $-24.27 Million | -4.028x | +34.08% |
| 2009-12-31 | $4.49 Million | $-27.41 Million | -6.110x | -110.38% |
| 2008-12-31 | $10.93 Million | $-31.75 Million | -2.904x | -283.16% |
| 2007-12-31 | $38.78 Million | $-29.39 Million | -0.758x | +72.74% |
| 2006-12-31 | $14.32 Million | $-39.83 Million | -2.781x | -67.99% |
| 2005-12-31 | $34.84 Million | $-57.67 Million | -1.655x | -4.74% |
| 2004-12-31 | $21.10 Million | $-33.34 Million | -1.580x | -63.71% |
| 2003-12-31 | $24.30 Million | $-23.46 Million | -0.965x | -6.06% |
| 2002-12-31 | $14.76 Million | $-13.44 Million | -0.910x | -26.31% |
| 2001-12-31 | $17.62 Million | $-12.70 Million | -0.721x | -102.25% |
| 2000-12-31 | $16.44 Million | $-5.86 Million | -0.356x | +73.23% |
| 1999-12-31 | $3.11 Million | $-4.14 Million | -1.331x | +31.49% |
| 1998-12-31 | $3.50 Million | $-6.80 Million | -1.943x | -319.66% |
| 1997-12-31 | $10.80 Million | $-5.00 Million | -0.463x | +64.73% |
| 1996-12-31 | $1.60 Million | $-2.10 Million | -1.313x | -89.00% |
| 1995-12-31 | $3.60 Million | $-2.50 Million | -0.694x | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more